NYSE:LLYPharmaceuticals
Eli Lilly (LLY) Wins FDA Approval For Mounjaro Heart Risk Reduction
Eli Lilly (NYSE: LLY) received FDA approval for Mounjaro to reduce major cardiovascular risk in adults with type 2 diabetes who are at high risk.
The new indication expands Mounjaro’s approved use beyond blood sugar control to include cardiovascular risk reduction.
The decision could influence how clinicians position Mounjaro in care plans for adults with type 2 diabetes and elevated cardiovascular risk.
Payers may factor the cardiovascular indication into future coverage and reimbursement...